These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 25687713)
1. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies]. Mühlbacher AC; Kaczynski A Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713 [TBL] [Abstract][Full Text] [Related]
2. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Mühlbacher A; Bethge S Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548 [TBL] [Abstract][Full Text] [Related]
3. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623 [TBL] [Abstract][Full Text] [Related]
4. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594 [TBL] [Abstract][Full Text] [Related]
5. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406 [TBL] [Abstract][Full Text] [Related]
6. Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. Mühlbacher AC; Sadler A; Juhnke C Eur J Health Econ; 2021 Apr; 22(3):425-443. PubMed ID: 33587221 [TBL] [Abstract][Full Text] [Related]
7. Patient preferences for diabetes treatment attributes and drug classes. Flood EM; Bell KF; de la Cruz MC; Ginchereau-Sowell FM Curr Med Res Opin; 2017 Feb; 33(2):261-268. PubMed ID: 27779433 [TBL] [Abstract][Full Text] [Related]
8. The patient perspective of diabetes care: a systematic review of stated preference research. von Arx LB; Kjeer T Patient; 2014; 7(3):283-300. PubMed ID: 24691766 [TBL] [Abstract][Full Text] [Related]
9. Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Janssen EM; Hauber AB; Bridges JFP Value Health; 2018 Jan; 21(1):59-68. PubMed ID: 29304942 [TBL] [Abstract][Full Text] [Related]
10. Patient preferences for noninsulin diabetes medications: a systematic review. Purnell TS; Joy S; Little E; Bridges JF; Maruthur N Diabetes Care; 2014 Jul; 37(7):2055-62. PubMed ID: 24963113 [TBL] [Abstract][Full Text] [Related]
11. A quantitative assessment of patient barriers to insulin. Casciano R; Malangone E; Ramachandran A; Gagliardino JJ Int J Clin Pract; 2011 Apr; 65(4):408-14. PubMed ID: 21401829 [TBL] [Abstract][Full Text] [Related]
12. A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. Janssen EM; Segal JB; Bridges JF Patient; 2016 Oct; 9(5):465-79. PubMed ID: 27120338 [TBL] [Abstract][Full Text] [Related]
13. Feature selection and classification model construction on type 2 diabetic patients' data. Huang Y; McCullagh P; Black N; Harper R Artif Intell Med; 2007 Nov; 41(3):251-62. PubMed ID: 17707617 [TBL] [Abstract][Full Text] [Related]
14. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Hauber AB; Mohamed AF; Johnson FR; Falvey H Diabet Med; 2009 Apr; 26(4):416-24. PubMed ID: 19388973 [TBL] [Abstract][Full Text] [Related]
15. [Objective Criteria in the Medicinal Therapy for Type II Diabetes: An Analysis of the Patients' Perspective with Analytic Hierarchy Process and Best-Worst Scaling]. Mühlbacher AC; Bethge S; Kaczynski A; Juhnke C Gesundheitswesen; 2016 May; 78(5):326-36. PubMed ID: 25853782 [TBL] [Abstract][Full Text] [Related]
16. Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. Ozdemir S; Baid D; Verghese NR; Lam AY; Lee PC; Lim AY; Zhu L; Ganguly S; Finkelstein EA; Goh SY Value Health; 2020 Jul; 23(7):842-850. PubMed ID: 32762985 [TBL] [Abstract][Full Text] [Related]
17. The Influence of Varying Cost Formats on Preferences. Jiang CC; Fraenkel L Med Decis Making; 2017 Jan; 37(1):17-26. PubMed ID: 27856826 [TBL] [Abstract][Full Text] [Related]
18. Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. Choi SE; Berkowitz SA; Yudkin JS; Naci H; Basu S Med Decis Making; 2019 Apr; 39(3):239-252. PubMed ID: 30767632 [TBL] [Abstract][Full Text] [Related]
19. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect? Allen D; Rixson L Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815 [TBL] [Abstract][Full Text] [Related]
20. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280 [No Abstract] [Full Text] [Related] [Next] [New Search]